MB

Megan Blewett

Co-founder and President

Berkeley, California

Invests in

Stages:

  • Min Investment:

    $10,000.00
  • Max Investment:

    $100,000.00
  • Target Investment:

    $50,000.00

Work Experience

  • Co-Founder and President

    2024

  • Co-Founder and VP Corporate Development

    2021 - 2024

  • Board Member

    2022

2019 - 2021

  • Co-Founder and Director of Business Development

    2019 - 2021

    Together with Venrock partner Bryan Roberts and scientific founders Michael Birnbaum and Michael Fischbach, I helped launch lentiviral gene therapy company Kelonia Therapeutics. The Birnbaum Lab had developed a highly elegant way to target lentiviruses to specific cell types, and it was our job to build a company leveraging this technology to treat serious diseases. Most of my time was focused on indication selection strategy and business development, but what I'm most proud of is helping to recruit the founding team.

2017 - 2020

  • Life sciences investor

    2017 - 2020

    - Board observer at Federation Bio, worked on company incubation and launch - Board observer at Prothelia - Co-founder at Iris Medicine - Co-founder at Kelonia Therapeutics